EUVIMEDEUVIMED entdecken
Crossref

7-Year (2015–21) longitudinal surveillance of lefamulin in vitro activity against bacterial pathogens collected worldwide from patients with respiratory tract infections including pneumonia and characterization of resistance mechanisms

Susanne Paukner iD, Rodrigo E Mendes iD, S J Ryan Arends iD, Gisela Gassner, Steven P Gelone, Helio S Sader iD

Journal of Antimicrobial Chemotherapy · 2024

DOI: 10.1093/jac/dkad389 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2024. Verfasst von Susanne Paukner und 5 weiteren Autor:innen. Beteiligte Einrichtung: Nabriva Therapeutics GmbH, Leberstrasse 20, A-1110 Vienna, Austria. Hauptthemen laut MEDLINE: Respiratory Tract Infections, Pneumonia, Community-Acquired Infections, Diterpenes. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 56 Literaturangaben. Gefördert von: Nabriva Therapeutics.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Lefamulin (Xenleta™), a pleuromutilin antibiotic, was approved for the oral and IV treatment of community-acquired bacterial pneumonia (CABP) in adults in 2019/2020. This study evaluated the in vitro activity of lefamulin and comparators against 19 584 unique bacterial isolates collected from patients with community-acquired respiratory tract infections and hospitalized patients with pneumonia within the global SENTRY Antimicrobial Surveillance Program during 2015–21.

Methods

Isolates were susceptibility tested by the CLSI broth microdilution method, and resistance mechanisms were investigated in isolates with elevated lefamulin MICs.

Results

Lefamulin exhibited potent antibacterial activity against the most common and typical CABP pathogens tested, including Streptococcus pneumoniae [MIC50/90, 0.06/0.25 mg/L; 99.9% susceptible (S)], Staphylococcus aureus (MIC50/90, 0.06/0.12 mg/L; 99.6% S), Haemophilus influenzae (MIC50/90, 0.5/2 mg/L; 99.1% S) and Moraxella catarrhalis (MIC50/90, 0.06/0.12 mg/L; 100.0% S). Potent activity was also observed against the less common pneumonia pathogens: β-haemolytic (MIC50/90 of 0.03/0.06 mg/L) and viridans group Streptococcus spp. (MIC50/90 of 0.06/0.25 mg/L) and Haemophilus parainfluenzae (MIC50/90 of 1/4 mg/L). Lefamulin’s activity was not adversely affected by resistance to macrolides, penicillin, tetracyclines, fluoroquinolones and other resistance phenotypes. Non-susceptibility/resistance to lefamulin was rare and primarily determined by ribosomal protection through vga(A) variants in S. aureus, overexpression of AcrAB-TolC efflux pump in H. influenzae or modifications in L3, L4 and 23SrRNA in Streptococcus spp.

Conclusions

Based on the coverage of the most important CABP pathogens and lacking cross-resistance, lefamulin may represent a valuable empirical treatment option for ambulatory and hospitalized patients with CABP, particularly in settings with high prevalence of resistance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Respiratory Tract InfectionsPneumoniaCommunity-Acquired InfectionsDiterpenesPolycyclic CompoundsThioglycolatesHumansStaphylococcus aureusAnti-Bacterial AgentsBacteriaMicrobial Sensitivity TestsHaemophilus influenzae

Substanzen

lefamulinAnti-Bacterial AgentsDiterpenesPolycyclic CompoundsThioglycolates

Autor:innen und Institutionen

  • Nabriva Therapeutics GmbH, Leberstrasse 20, A-1110 Vienna, Austria.
  • JMI Laboratories, 345 Beaver Kreek Center, Suite A, North Liberty, IA 52317, USA.
  • Nabriva Therapeutics US Inc., 414 Commerce Drive, Suite 120, Fort Washington, PA 19034, USA.

ORCID-Profile: Susanne Paukner, Rodrigo E Mendes, S J Ryan Arends, Helio S Sader

Förderung

  • Nabriva Therapeutics

Zitieren

APA

Paukner, S., Mendes, R. E., Arends, S. J. R., Gassner, G., Gelone, S. P., & Sader, H. S. (2024). 7-Year (2015–21) longitudinal surveillance of lefamulin in vitro activity against bacterial pathogens collected worldwide from patients with respiratory tract infections including pneumonia and characterization of resistance mechanisms. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkad389

Vancouver

Paukner S, Mendes RE, Arends SJR, Gassner G, Gelone SP, Sader HS. 7-Year (2015–21) longitudinal surveillance of lefamulin in vitro activity against bacterial pathogens collected worldwide from patients with respiratory tract infections including pneumonia and characterization of resistance mechanisms. Journal of Antimicrobial Chemotherapy. 2024. doi:10.1093/jac/dkad389

BibTeX
@article{Paukner2024,
  author = {Paukner, Susanne and Mendes, Rodrigo E and Arends, S J Ryan and Gassner, Gisela and Gelone, Steven P and Sader, Helio S},
  title = {7-Year (2015–21) longitudinal surveillance of lefamulin in vitro activity against bacterial pathogens collected worldwide from patients with respiratory tract infections including pneumonia and characterization of resistance mechanisms},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2024},
  doi = {10.1093/jac/dkad389}
}
Kostenlos starten →